AKRO — Akero Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Akero Therapeutics Reports 36-Week Analysis Of 96-Week Phase 2B Symmetry Study
U.S. STOCKS ON THE MOVE-China ADRs, Lexicon Pharma, PepsiCo
Akero's drug for fatty liver disease misses main trial goal (updated)
Akero's drug for fatty liver disease misses main trial goal
Akero to share NASH drug trial results on Oct. 10, stock rises
Brief: Akero Therapeutics Announces Publication Of The Harmony Phase 2B Trial Results
U.S. RESEARCH ROUNDUP-Automatic Data Processing, Hudson Pacific Properties, Oracle
U.S. STOCKS ON THE MOVE-Danaher, Goldman Sachs, Generac Holdings
U.S. STOCKS ON THE MOVE-3M, RPT Realty, CN Energy
Akero gains as UBS bullish on NASH drug, sets Street-high PT
Brief: Akero Therapeutics To Report Results Of Phase 2B Symmetry Study In October 2023
U.S. RESEARCH ROUNDUP-Dollar Tree, Hexcel, Humacyte
Akero Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Pfizer makes equity investment in Caribou Biosciences
89Bio up as Evercore starts with 'outperform', says NASH asset undervalued
U.S. STOCKS ON THE MOVE-Spotify, Akero Therapeutics, Cyxtera Technologies
Akero Therapeutics rises on positive data from fatty liver therapy study
Brief: Akero Therapeutics Anticipates Cash, Cash Equivalents And Short-Term Marketable Securities Of About $660 Million As Of June 2
Brief: Akero Therapeutics’ Phase 2B Symmetry Cohort D Study Meets Safety, Tolerability Endpoints